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ABSTRACT 
 
 Although modern medicine made great steps toward curing most diseases considered 
deadliest, yet cancer remains one of the major public health problems. The first part of this thesis 
investigates a new source of selective compounds that are potential candidates against cancer. 
Fifteen Russian compounds were tested in order to establish their efficiency against two types of 
cancer: human breast SK-Br-3 and colorectal carcinoma HT-29. The bioassay results show that 
seven of the new synthetic Russian compounds can be considered new drug leads, based upon 
their low toxicity and efficacy in slowing the growth of human breast cancer and colon cancer 
cells.  
 The goal of the second part of the thesis was to isolate pure compounds that inhibit the 
growth of cancer cells from the methylene chloride extract of Eucalyptus viminalis Labill. This 
plant was selected for investigations since a preliminary screening of plants from Russia 
indicated that had activity against cancer. The result of this work was the isolation of a pure 
compound which has been analyzed using different spectroscopic techniques such as MS, HPLC, 
1H-NMR, DEPT, 13C-NMR. The extracted compound was β-amyrin formate, which was 
previously reported by Malhotra49, from Canarium strictum Gum in 1987. Also, the bioassay 
results indicated that β-amyrin formate might be considered a possible drug lead against colon 
cancer and can be recommended for further investigations. This is the first report of isolation of 
β-amyrin formate from Eucalyptus viminalis Labill and the first test of the activity of this 
compound against colon cancer.  
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PART I: EVALUATION OF RUSSIAN SYNTHETIC COMPOUNDS AS A 
POTENTIAL SOURCE OF NEW DRUG LEADS AGAINST BREAST AND 
COLON CANCER 
 
1. Introduction 
 
 This study is dedicated to a search for new sources of active and selective compounds 
against cancer. Fifteen Russian synthetic compounds were tested as inhibitors against two cancer 
cell lines: human breast and colorectal carcinoma. The relentless attack by cancer on humans 
continues to demand a devastating toll. On a world-wide basis the devastation caused by cancer 
is staggering to contemplate. Fortunately, the increased use of well-established anticancer drugs 
combined with overall advances in cancer treatment has markedly increased survival time for 
most cancer patients. The nation's investment in cancer research is making a difference. Yet 
cancer remains a major public health problem.1The majority of most useful and curative 
anticancer drugs continue to be derived from plant and animal sources. Doubtlessly, anticancer 
drugs of biosynthetic origin will continue to be of accelerating importance in improving cancer 
treatment and overall survival rates.  
Breast cancer is a significant health problem for women in the United States and throughout 
the world. Although advances have been made in detection and treatment of the disease, breast 
cancer remains the second leading cause of cancer-related deaths in women, affecting more than 
180,000 women in the United States each year. For women in North America, the life-time odds 
of getting breast cancer are now one in eight. No vaccine or other universally successful method 
for the prevention or treatment of breast cancer is currently available. Management of the disease 
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currently relies on a combination of early diagnosis (through routine breast screening 
procedures) and aggressive treatment, which may include one or more treatments, such as 
surgery, radiotherapy, chemotherapy and hormone therapy.2 The most recent studies were 
focused on developing new and modern methods to assist patients with breast cancer. One 
method analyzes the correlation  between immunohistochemical analysis and fluorescence in situ 
hybridization (FISH) in HER-2 status and studied the effect of dual-color (D-FISH) versus 
single-color FISH (S-FISH) scoring on the assignment of tumors to amplified or nonamplified 
categories.3 Recent advances in radiation methods provide a new technique which is called 
accelerated partial breast irradiation (APBI) after breast-conserving surgery. APBI has very 
recently come to the forefront as a potential local treatment option for women with breast 
cancer.4 The use of modern techniques in radiotherapy planning is recommended to minimize 
excessive normal tissue exposure, particularly to the cardiac and pulmonary structures. A new 
method related to this issue is loco regional post-mastectomy radiotherapy (PMRT). The optimal 
sequencing of PMRT and systemic therapy is currently unclear.5
Hormone therapy is a very important part in breast cancer treatment. Many drugs have been 
mentioned in the BCCA Cancer Drug Manual and other sources as being potentially applicable 
to breast cancer. The mechanism of action is the following: Aromatase catalyzes the final and 
rate-limiting step in the conversion of androgens to estrogens in peripheral tissues. This occurs 
mainly in adipose tissue, but also in normal and malignant breast tissues, and provides the main 
source of estrogen in postmenopausal women. The goal of hormone therapy in breast cancer is to 
deprive tumor cells of estrogens, which are implicated in the development or progression of 
tumors.11,12  
 2
Aminoglutethimide (Cytadren)6 is a simple chemical derivative of the sedative gluthethimide. It 
was originally introduced as an anticonvulsant, but it was found to cause adrenal insufficiency. It 
blocks adrenal steroidogenesis by inhibiting the enzymatic conversion of cholesterol to 
pregnenolone.7,8,9,10  
Et
O
NH
O NH 2
(1)  p-Aminoglutethimide 
 
Anastrozole (Arimidex)6 is a reversible, nonsteroidal aromatase inhibitor.  
MeMe
Me
Me
CN
CN
C
C
CH 2N
N
N
 (2)  Anastrozole 
 
  Tamoxifen (Nolvadex)6 was first approved in the United Kingdom in 1973, and in 1977 gained 
approval in the United States. It is an estrogen antagonist, structurally related to the synthetic 
estrogen diethylstilbestrol. The precise mechanism of action is uncertain.  
Et
Me 2N
Ph
Ph
O
Z
 (3)  trans-Tamoxifen 
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Gemcitabine15 is a pyrimidine analog which is metabolized intracellularly to two active 
metabolites, gemcitabine diphosphate and gemcitabine triphosphate. 
F
F
ON
OH
ON
OH
H2N
R
R
R (4)  Gemcitabine 
 
Tibolone has estrogenic, progestogenic and androgenic activity. There is great concern regarding 
the effects that hormone replacement therapy (HRT) might have on the risk of breast cancer. 
This product has emerged as an alternative to conventional HRT in the treatment and prevention 
of the effects of estrogen deficiency in postmenopausal women. Preclinical data suggest that 
tibolone behaves mainly as a progestin in breast cell lines, and does not promote tumor 
development in tumor models. Tibolone appears to be a safe and acceptable alternative to HRT. 
However, further studies are required in order to achieve more reliable conclusions.16
Me
Me C
OH
O
CH
H
H HR
R
SS
S R
(5)  Tibolone 
 
Vinorelbine (Navelbine)6 is a semisynthetic vinca alkaloid derived from vinblastine. Vinca 
alkaloids are originally derived from periwinkle leaves (vinca rosea)17. 
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      The call for the discovery of more effective agents to treat cancer has become urgent. 
Recently, new compounds called “diazenes” were synthesized. It was demonstrated that several 
of them inhibited the growth of tumor cells, but their biological activity was relatively low. 
Therefore, new compounds have been synthesized to improve biological activity. The most 
active diazenes and their derivatives were tested also on human breast carcinoma.18
The incidence of hormone-dependent cancers, such as those of the breast and prostate, is 
much lower in Eastern countries such as China and Japan in comparison with the Western world. 
Diet is believed to have a major effect on disease risk and one group of compounds, the 
phytoestrogens, have been implicated in cancer protection. The phytoestrogens are comprised of 
two main groups: the isoflavone and lignans. Of the isoflavones, genistein and daidzein have 
been the most widely studied. These compounds have been shown to possess anticancer 
properties; however their precise mechanism of action remains to be elucidated19. In comparison, 
few studies have investigated the effects of lignans in breast and prostate cancer19. In vitro 
studies have shown that genistein exerts biphasic effects on cancer cell growth, stimulating 
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growth at low concentrations (<10µM) and inhibiting growth at high concentrations (>10 µM), 
which suggest that low phytoestrogen levels may stimulate cancer growth in vivo.  
O
O
OH
HO
OH
O
OHO
OH
(7)  Genistein 
(8)  Daidzein 
 
An important class of compounds which show anti-tumor activity is represented by pyrrole 
derivatives. Thirty nine35 derivatives of the 2,5-dihydropyrrole-2,5-dione were synthesized and 
tested. The 1-benzyl-3-chloro-4-(3-hydroxyanilino)-2,5-dihydro-1H-2,5-pyrroledione was 
selected after pre-screening and tested on 56 cell lines of human tumors and exhibits anti-tumor 
activity against breast cancer. Also, 4-oxo-butenoic acids and related compounds were prepared, 
tested and claimed useful for the treatment of breast carcinoma.36
OEt
OMe
N
NH
C
CH
C
C
O
O (10)  2-Butenoic acid,    4-(4-ethoxyphenyl)-2- 
        (9H-fluoren-9-ylidenehydrazino)- 
        -4-oxo-, methyl ester  
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      Various active compounds (or their semi-synthetic derivatives) derived from medicinal plants 
have been assessed for their efficacy and tolerability in the treatment of breast cancer. Some of 
these plant species, including Taxus baccata (docetaxel, see compound 9), Podophyllum 
peltatum (etoposide), Camptotheca acuminate (camptothecin) and Vinca rosea (vinblastine, 
vinorelbine, see compound 6) have well recognized anti-tumor activity in breast cancer, and have 
been evaluated in clinical trials. Docetaxel (Taxotere)6 is a semi-synthetic drug derived from a 
precursor extracted from the needles of the European yew tree, Taxus baccata13. It acts by 
disrupting the microtubular network that is essential for mitotic and interphase cellular functions. 
t-BuO
AcO
MeMe
Me
Me
Ph
Ph O
O
OH
OHO
O
HO
O
O
OH
NH
O H
H
SR R
S
S
S
S
R
SRS (9)  Docetaxel 
 
 A recent study considers interaction between Trastuzumab, Carboplatin, and Docetaxel highly 
synergistic, even at very low drug concentrations.14 For example, results from recent Phase II /III 
trials have established docetaxel as the most active single agent in the treatment (first or second-
line) of advanced metastatic breast cancer. For other plant species, such as Panax ginseng and 
Allium sativum, anti-tumor activity has been evaluated in experimental studies using cultured 
cells and animal models, but the therapeutic potential in patients remains to be determined. Anti-
tumor activity derived from medicinal plants may produce results via a number of mechanisms, 
including effects on cytoskeletal proteins, which play a key role in mitosis (paclitaxel), inhibition 
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of activity of topoisomerase enzymes I (camptothecin) or II (etoposide), stimulation of the 
immune system (Viscum album), or antiprotease-antioxidant activity. Medicinal plant-derived 
antineoplastic agents may be used in single agent or in combinational therapies, and have been 
used in first-line or second-line (including anthracycline-refractory patients) treatment of 
localized or metastatic breast cancer20.   
      Colorectal cancer is the second leading cause of cancer-related deaths and is responsible for 
about 12% of cancer deaths in the United States. The mortality rate of newly diagnosed large 
bowel cancer approaches 50% and there has been little improvement over the past 40 years. Most 
of this mortality reflects local, regional, and distant metastases. About thirty percent of patients 
with colorectal cancer have unresectable disease at presentation and about 40% develop 
metastases during the course of their disease. Surgery is the mainstay of treatment for colorectal 
cancer but recurrence is frequent.21 Colorectal cancer has proven resistant to chemotherapy, 
although limited success has been achieved.  
       Traditional therapies for colorectal cancer include surgery, radiation therapy and 
chemotherapy with 5-fluorouracil and levamisole, being the preferred chemotherapeutic agents 
for colorectal adenocarcinoma.22. Fluorouracil6 was developed in 1957, based on the observation 
that tumor cells utilized the base pair uracil for DNA synthesis more efficiently than normal cells 
of the intestinal mucosa. It is a fluorinated pyrimidine that is metabolized intracellularly to its 
active form, fluorodeoxyuridine monophosphate (FdUMP). The active form inhibits DNA 
synthesis by inhibiting the normal production of thymidine. Fluorouracil is cell cycle phase-
specific (S- phase).23,24 
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F
O
NH
NHO
(11)  Fluorouracil 
 
In 1971, it was reported that Levamisole, a drug that had been originally designed for 
anthelminthic properties, had immunostimulatory properties in vivo. Levamisole is a synthetic 
imidazothiazole derivative that has been widely used in treatment of worm infestations in both 
humans and animals. It may function as a modulating agent to increase the action of fluorouracil.  
Its mechanism of action as adjuvant therapy in cancer has not been determined.7,9
PhN
N
S
S (12)  Levamisole 
 
       Many compounds were tested against human tumor cell lines. One of them is 2-chloro-9-(2-
deoxy-2-fluoro-β-D-arabinofuranosyl) adenine (Cl-F-ara-A). The compound showed selectivity 
in vivo, with excellent activity being demonstrated against human colon tumors.25
F
Cl
NH 2
N
N
N
N
O
OH
OHR
S
R
R
(13)  Cl-F-ara-A 
 
Several nonsteroidal anti-inflammatory drugs (NSAIDs) which have antiproliferative activity in 
colon cancer cells, are carboxylate compounds forming acyl glucuronide metabolites. It was 
demonstrated that acyl glucuronides (and isomers) of the carboxylate NSAIDs diflunisal, 
zomepirac and diclofenac had antiproliferative activity on human adenocarcinoma HT-29 cells in 
 9
culture.26 Ammonia, produced by bacterial degradation of unabsorbed and edogeneous 
nitrogenous compounds, is found to be present at millimolar concentrations in the colon lumen. 
From in vivo animal experiments, this metabolite has been shown to alter colonic epithelial cell 
morphology and to increase compensatory cell proliferation when present in excess. Ammonia 
was not metabolized by HT-29 cells into carbamoyl-phosphate and citrulline, indicating that 
ammonia was likely acting on cells by itself. This agent was shown to significantly reduce 
cellular ornithine decarboxylase (ODC) activity, resulting in a threefold decrease in the capacity 
of HT-29 cells to synthesize polyamines, these latter metabolites being strictly necessary for cell 
growth. The unexpected finding that ammonia is acting as an antimitotic agent against tumoral 
HT-29 colonic cells may be related to the inability of these cells to metabolize this compound.27
The in vitro cytotoxic activity profile of nine novel phenylarsonic acid compounds against 17 
human cancer cell lines, including colon cancer and breast cancer, was determined. The leads 
compounds, 2-methylthio-4-[(4’-aminophenylazo)-phenylarsonic acid] pyrimidine (PHI-370) 
and 2-methylthio-4-(4’-phenylarsonic acid)-amino pyrimidine (PHI-380) caused apoptotic death 
in all 17 cancer cell lines at low micromolar concentrations. PHI -380 was also tested and found 
to be very active against primary tumor cells isolated from surgical biopsy specimens of 14 
patients with therapy-refractory breast cancer, colon cancer, lymphoma or hepatoblastoma as 
well.28
 10
SMe
NH N
N
NN
As
O
HO
OH
(14)  PHI 370 
SMe
NH N
N
As
O
HO
OH
(15)  PHI 380 
 
Quinazoline compounds have been suggested as useful compounds in the treatment of cell 
growth and differentiation characterized by activity of the human epidermal growth factor 
receptor type2 (HER2) (see Myers et.al., U.S. Pat. No. 5,721,237). A method of preventing the 
development or recurrence of colorectal cancer in a mammal is administering an effective cancer 
preventative amount of 4-(4’-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline or a 
pharmaceutically acceptable salt thereof to the mammal.31
MeO
MeO
NH
N
N
OH
(16)  Janex 1 
 
       Methods for the prevention and treatment of colorectal cancer are provided. Specifically, the 
method relates to the administration of an effective adenoma or microadenoma preventing 
amount of 6-fluoroursodeoxycholic acid (6-FUDCA) or a pharmaceutically acceptable conjugate 
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thereof to a mammal in need of such treatment. The methods find general use in the prevention 
of the formation of secondary bile acids, the reduction of deoxycholic acid and the protection 
against cytotoxic effects of other bioacids and carcinogens.29
Me
Me
Me CO 2H
F
OHHO
H
H H
H
H
R
S
R
S
R
S
RR
R R
R
(17)  6-FUDCA 
 
Another method for colon cancer chemoprevention or chemotherapy is administering a 
pharmaceutical composition comprising of an effective amount of a 2-hydroxy-5-
phenylazobenzoic acid derivative or an ester or an active metabolite or an oxidation product of 
an active metabolite thereof to an individual suffering from colon cancer or at risk to develop 
colon cancer.30
OMe
Ph
C
O
N N
OH
(18)  5-Hydroxy-2-phenylazobenzoic 
               acid methyl ester 
 
         Immunotherapy uses different ways to stimulate the immune system and stop cancer cells 
for growing. Immunotherapy biological extracts may be useful as adjuvant therapy in treating 
patients who have had surgery for breast cancer, colon cancer, or melanoma.34
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2. Results and Discussion 
 
2.1. Goal of study 
 
The main goal of this work was to test new synthetic compounds with different functional groups 
against breast and colon cancer. The compounds chosen had pyrrolone, pyruvic acid and aryl 
fluoride moieties, which are found in many nitrogen heterocyclics with demonstrated biological 
activity as mention previously. The results of this study will be the selection of new drug leads, 
based upon their low toxicity and efficacy in slowing the growth of human breast cancer and 
colon cancer cells. Also, one can establish whether they have potential to be considered for 
further investigations related to the mechanistical mode of action. The structures of the synthetic 
Russian compounds are shown in Table 1. 
 
Table 1. Russian synthetics 
 
General Structure Radicals Notation 
R1 = p-CH3C6H4
R2 = C6H4Br-p 
3F-1 
R1= p-C2H5OC6H4
R2= (CH3)2C6H4
3F-2 
R1= C6H5
R2= (CH3)2C6H4
3F-3 
R1= C6H5
R2 = p-CH3C6H4
3F-4 
R1= p-C2H5OC6H4 
R2= p-CH3C6H4
3F-5 
R1= (CH3)3C 
R2= p-CH3C6H4
3F-6 
    
N O
OH
H3COOC
HO
R1-CO
R2  
R1= C6H5
R2= C6H5COOC2H5
3F-7 
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R1= p-H3OC6H4  
R2 = COOH 
3F-10 
R1= p-ClC6H4 
R2 = C6H5
3F-11 
CCO CO
NNHC6H5
R2R1
 
R1= p-C2H5OC6H4
R2 = COOCH3
3F-12 
F F
H3CO
F F
C COOCH3
O OH
 
            
3F-13 
F F
H3CO
F F
C COOCH3
OO
Cu/2  
 3F-14 
N
p-CH3C6H4CO
OH
OH
O
N
C6H5  
 3F-16 
F
CH3O
F
F
O
O
COOCH3
 
 3F-18 
 14
CHCO C COOCH3
N
NH C C6H5
C6H4Br-o
p-ClC6H4
 
 3F-20 
 
 
2.2. Bioassay of Russian synthetics 
 
  Both cell lines   (human breast carcinoma SK-Br-3 and colorectal HT-29) were ordered 
from American Type Culture Collection and they were derived independently from different 
patients. All cells were cultured in the same medium, with identical composition and they were 
split and fed by the same procedure. The actual bioassay was performed on both cell lines and 
the compounds were tested in the same way. Five plates were used and they were seeded in the 
same time with 3 mL of medium each (initial dose). For the first two intervals of time (0-48 hrs 
and 48-96 hrs), one plate was chosen each time to be read, which means counting the number of 
cells. All other plates were only fed with 3 mL of medium each. The third interval of time (96-
120 hrs) is considered critical for observations and counting number of cells; that is why the 
plates were not fed and only one plate was read. The last two intervals of time (120-144 hrs and 
144-168 hrs) were similar to the first two intervals: one plate was read each time and the 
remaining ones were only fed. Total volume needed of drug and medium for the entire assay is 
39.0 mL, but 50 mL were used for variations in pipeting. Initial screening of any compound, 
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tested solely for activity, was done by using 10 µg/mL concentration of compound and the 
sample calculation for 50 mL of a compound weighed out at 0.0018 g is as following: 
(1800 µg/mL) X = (10 µg/mL) (50.0 mL) 
X = 0.278 mL  
The drug solution was prepared by adding 280 µL of drug to 49.720 mL of medium. 
The final step on the bioassay test was to count the variation in number of cells for each 
compound and compare them to a control sample (a sample without any drug added). The counts 
were done by using a device called a hemacytometer. Once all the counts were finished for all 
periods of time, all numbers were added up, then they were divided by 24 and the result was 
multiplied by 104. This represents the hemacytometer formula. The results were recorded, and 
the logarithm from number of cells/mL was plotted versus time. The variation percent of breast 
and colon cancer cells was calculated for two intervals of time: 48-96 hrs and 96-120 hrs. Also, 
the average of the variation percent for both intervals of time was determined. The variation 
percent for the first time interval is given by the following formula:  
                          I(%) =[S (96h) – S (48h) / C(96h) – C(48h)] ×100 
Where S (96h) and S(48h) represent the number of breast or colon cancer cells counted at 96 and 
48 hours respectively for each synthetic derivative. 
C(96h) and C(48h) represent the number of breast or colon cancer cells counted at 96 and 48 
hours respectively for control wells (no drug added).  Also, the same formula was applied for the 
second time interval, 96-120 hours. A negative number represents an inhibition of growth of 
cancer cells. That means the number of cancer cells is decreasing in time, as opposed to the 
number of control cells (cells with no drugs added). A positive number represents a growth of 
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cancer cells. That means the number of cancer cells is increasing in time, in a similar way to the 
control cells. In order to be considered a possible drug lead, one compound must have a percent 
inhibition of 15-30% for the considered interval of time. A very high inhibition indicates that the 
effect of the drug is undesirable because it could be toxic to normal and cancer cells35. On the 
contrary, a very high growing rate, which corresponds to a positive number in the table, is also 
not valuable because of its failure in suppressing the growth of cancer cells. 
 
2.3. Inhibition of human breast cancer cells   
 
 The results for testing the compounds against breast cancer cells are shown in Table 2. As 
we have mentioned previously, two intervals of time were considered, 48-96 hrs and 96-120 hrs. 
Also the average of the normalized variation of breast cancer cells for both intervals of time was 
calculated.  
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Table 2. Variation percent of breast cancer cells 
 
Comp. 48-96 (hours) 96-120 (hours) Avg. 
3F-1 13 -29 -8 
3F-2 -13 55 21 
3F-3 -45 75 15 
3F-4 -39 29 -5 
3F-5 -31 13 -9 
3F-6 -16 103 44 
3F-7 -24 -15 -20 
3F-10 -76 5 -36 
3F-11 -25 23 -1 
3F-12 -44 -42 -43 
3F-13 -9 -66 -38 
3F-14 -6 -43 -25 
3F-16 -5 -6 -6 
3F-18 -4 5 1 
3F-20 7 -22 -8 
 
 
 From Table 2 and Figure 1 (pyrrolone derivatives) one can conclude that for the first 
interval of time (48-96 hours) the 3F-1 compound shows a growth in cell number (13 %). All 
others show inhibition of cancer cells and the most valuable are considered to be 3F-5 (-31%), 
3F-7 (-24%) and 3F-6 (-16%). 3F-2 (-13%) did not show a very significant inhibition. There is a 
toxicity problem associated with the 3F-3 ( -45%) and 3F-4 ( -39%) compounds. For the second 
interval of time (96-120 hrs), 3F-1 (-29%) and 3F-7 (-15%) show inhibition of cancer cells. All 
other pyrrolone derivatives cannot be considered inhibitors of breast cancer cells.  
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Figure 1. Effect of pyrrolone derivatives relative to the growth of breast cancer cells 
  
 
From Table 2 and Figure 2, one can conclude that 3-acylsubstitute derivative 3F-10 ( -76%) is 
the most toxic compound, besides 3F-12 ( -44%), that means they cannot be used for more tests. 
The 3F-11 (-25%) indicates a good inhibition of cancer growth. None of them presents interest 
for further studies for the second interval of time. 
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Figure 2. Effect of 3-acylsubstitute derivatives relative to the growth of breast cancer cells 
 
 
 Based on Table 2 and Figure 3, for the first interval of time, substitute pyruvates 3F-13, 
3F-14, and 3F-18 show an inhibition of -9%, -6% and -4% respectively. These results cannot be 
considered significant for future studies.  For the second interval of time 3F-13 and 3F-14 show 
toxicity and the inhibitions are -66% and -43% respectively. 3F-18 shows a growth in cancer 
cells (5%). 
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Figure 3. Effect of substitute pyruvates relative to the growth of breast cancer cells 
 
 
 Based on Table 2 and Figure 4, compounds 3F-16 (-5%) and 3F-20 (7%) show no interest 
for further investigations on breast cancer, because the former has a very low inhibition and the 
latter shows no inhibition of growth. For the second interval of time, 3F-20 (-22%) might be 
considered as inhibitor of breast cancer cells. 
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Figure 4. Effect of 3F-16, 3F-20 derivatives relative to the growth of breast cancer cells 
 
 
 Thus, for the first interval of time, the only compounds which might be considered for 
further investigation are 3F-5, 3F-6, 3F-7 and 3F-11 compounds. For the second interval of time 
3F-1, 3F-7 and 3F-20 compounds might present interest for further studies. 
 
2.4. Inhibition of human colon cancer cells 
  
 The results for testing the compounds against colon cancer cells are shown in Table 3. As 
we have mentioned previously, two intervals of time were considered, 48-96 hrs and 96-120 hrs. 
Also, the average of the normalized evolution percent of breast cancer cells for both intervals of 
time was calculated.  
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Table 3. Variation percent of colon cancer cells 
 
Comp. 48-96 (hours) 96-120 (hours) Avg. 
3F-1 50 26 38 
3F-2 20 10 15 
3F-3 17 13 15 
3F-4 25 26 25 
3F-5 31 13 22 
3F-6 35 25 30 
3F-7 0 44 22 
3F-10 55 -17 19 
3F-11 5 -67 -31 
3F-12 -23 -45 -34 
3F-13 1 44 23 
3F-14 12 40 26 
3F-16 86 -66 20 
3F-18 49 31 40 
3F-20 66 13 40 
 
 
From Table 3 and Figure 5, one can see that pyrrolone derivatives did not present significant 
results related to the inhibition of growth of colon cancer cells. For both intervals of time all 
normalized variations are positive values, which mean no inhibition of colon cancer cells. 
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Figure 5. Effect of pyrrolone derivatives relative to the growth of colon cancer cells 
 
 
 Based on Table 3 and Figure 6, 3-acylsubstitute 3F-10 (-17%) shows an inhibition of 
growth of cancer cells for the second time interval (96-120 hours). 3F-11 (-67%) is the most 
toxic compound for both types of cells, besides 3F-12 (-45%). 3F-10 (55%) and 3F-11 (5%) 
show no inhibition of colon cancer cells for the first interval of time.  
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 Figure 6. Effect of 3-acylsubstitutes relative to the growth of colon cancer cells 
 
 
 Based on Table 3 and Figure 7 substitute pyruvates did not show significant results 
related to the inhibition of growth of colon cancer cells (all numbers show no inhibition of colon 
cancer cells for both intervals of time). These compounds cannot be taken in consideration for 
development of new drug leads against colon cancer. 
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Figure 7. Effect of substitute pyruvates relative to the growth of colon cancer cells 
 
 
 Table 3 and Figure 8 show a toxicity problem for the second interval of time (96-120 
hours) for 3F-16 (-66%). For the first interval of time there is no significant inhibition of colon 
cancer cells for 3F-16 and 3F-20 compounds. 
 26
 
Figure 8. Effect of 3F-16, 3F-20 relative to the growth of colon cancer cells 
 
 
2.5. Conclusion 
 
In conclusion, considering the relation between the structure of derivatives and the possible 
activity, the following general conclusions can be formulated:  Further investigations related to 
the inhibition of breast cancer cells might be useful for pyrrolone derivative 3F-5 (-31%), 3F-6 (-
16%) and 3F-7 (-24%) for the first interval of time (48-96 hrs). Also 3F-7 can be considered for 
investigations on the second interval of time. 3F-11 (-25%), which is a 3-acylsubstitute 
derivative, can also be taken in consideration for the first interval of time against growth of 
breast cancer cells. 3F-20 (-22%) can be considered for the second interval of time against 
growth of cancer breast cells. From experiments related to colon cancer cells 3-acylsubstitute 
derivative 3F-12 (-23%) and 3F-10 (-17%) show inhibition for the first interval of time and the 
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second interval of time respectively. Thus, further investigations might be useful for 3-
acylsubstitutes against colon cancer, focusing on studies primarily in the second interval of time 
(96-120 hours). Thus these synthetic compounds represent potential candidates as new drug 
leads and might be used in the treatment of breast and colon cancer. All these studies have the 
purpose to choose the most selective drug leads and to analyze their mechanism of action.  
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3. Experimental 
 
3.1. Cell lines, chemicals and reagents 
 
 Human breast carcinoma cell line (SK-Br-3) and colorectal cell line (HT-29) were 
obtained from American Type Culture Collection (ATCC, Manassas, VA). Both cell lines were 
derived independently from different patients. All cells were cultured in McCoy’s 5 a medium 
with 1.5 mM L- glutamine, fetal bovine serum (FBS) 10%, and antibiotic/antimicotic solution. 
Trypsin-EDTA solution was used for splitting cells. Other materials used were: specific bioassay 
glassware (ex: pipettes, flasks, centrifuge tubes, etc.), microscope, hemacytometer, centrifuge 
instrument, incubator, refrigerator, liquid nitrogen container. The protocol was presented in 
ATCC (American Type Culture Collection) catalog. 
 
3.2. Procedure  
 
 The standard operating procedure has two steps: maintenance of cancer cells and 
bioassay on cancer cells. 
A. Maintenance of cancer cells. 
A McCoy’s 5a medium was mixed with 1.5mM L- glutamine, 90%; fetal bovine serum 10% and 
antibiotic/antimicotic and represent the medium for growing cells. The cells were split with 1.0 
mL of Trypsin/EDTA solution and placed into the incubator for at least 10 minutes to help the 
cells dislodge.  The flask was removed from the incubator, and medium was added to a total 
volume of 5.0 mL. 1.0 mL of the mixture was added to a new flask containing fresh medium 1:5 
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split (ATCC recommends a sub cultivation ratio of 1:3 to 1:8). Freezing cells: This step was 
done during a normal split procedure using a centrifuge at 4000 rpm for 20 minutes, until the 
cells form a pellet. The supernatant was removed and discarded. 5.0 mL of 95% culture medium 
and 5% DMSO were centrifuged. The content was transferred into cryovials and placed into 
liquid nitrogen container. 
B. Performing bioassay on cancer cells: Preparation of stock drug. 
A mass of 0.0018 g of compound was weighted and dissolved in 1.0 mL of DMSO. 
Preparation of drug and medium for maintenance of cells in bioassay: 
This protocol was based on running two series of plateau at 5 plates per series. The plates were 
on the standard feeding schedule of every 48 hours. The compounds were tested in three wells 
per plate.  
Seeding of plates for bioassay: A standard 1:10 split procedure of the flask designated for 
bioassay was performed. From that, another 1:50 split was performed into three 50.0 mL 
centrifuge tubes, containing 49.0 mL of medium each. 
Each well to be used in the assay was seeded with 1.0 mL of the 1:500 split cells and was placed 
into the incubator. After 48 hours, the plates were dosed.  
Dosing of plates: The old medium was removed from the plates and 1.0 mL of the compound 
and medium combination that was previously prepared was added to each designated well. 
Reading the plates: The old medium was removed and a small amount of Trypsin/EDTA was 
added to wash away Trypsin inhibitors in fetal bovine serum. Exactly 1.0 mL of Trypsin was 
added to each well and placed into the incubator. 40 µL of sample was used to load the 
hemacytometer and perform the counts.  
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PART II: ISOLATION OF β-AMYRIN FORMATE FROM EUCALYPTUS 
VIMINALIS LABILL AND INVESTIGATION OF ITS COLON CANCER 
ACTIVITY  
 
1. Introduction 
 
 The goal of this work was to isolate pure compounds that inhibit the growth of cancer 
cells from the methylene chloride extract of Eucalyptus viminalis Labill. This plant was 
selected for investigations, since a preliminary screening of plants from Russia indicated that 
this plant had activity against cancer36. 
     While this plant material was collected in Russia, Eucalyptus is native to Australia, and 
the genus Eucalyptus contains about 600 species. Eucalyptus is a fast-growing tree that is 
utilized to manufacture paper. For this reason, there has been extensive overseas forest 
plantation of Eucalyptus trees. When trees are cut for biomass resources, the usage of leaves 
surplus is considered to be an important research subject. The Aborigines (native 
Australians) have traditionally used Eucalyptus leaves to heal wounds and fungal infections. 
The extracts of Eucalyptus leaves have been approved as food additives, and the extracts are 
also currently used in cosmetic formulations. Recently, attention has been focused on the 
medicinal properties of these extracts. Research data has demonstrated that the extracts 
exhibit various biological effects, such as antibacterial, antihyperglycemic (Gray and Flatt 
1998)37 and antioxidant (Lee and Shibamoto 2001)38 activities. The antimicrobial activities of 
leaf extracts from Eucalyptus viminalis significantly inhibited the growth of six Gram-
positive bacteria (Staphylococcus aureus, MRSA, Bacillus cereus, Enterococcus faecalis, 
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Alicyclobacillus acidoterrestris, Propionibacterium acnes), and of a fungus (Trichophyton 
mentagrophytes), but they did not show strong antibacterial activity against Gram-negative 
bacteria (Escherichia coli, Pseudomonas putida)39. 
     Previously, several compounds have been isolated from Eucalyptus viminalis, including 
ursolic acid40, maslinic acid41, 11,12-dehydroursolic acid lactone, eucalyptol42,α-pinene42,α-
terpenyl acetate42, grandinin43, pterocarinin A44. The structures of these compounds are 
shown in Table 6. Ursolic acid is a triterpenoid which occurs especially in the waxy coatings 
of the leaves and on fruits, such as apples and pears, and may serve as insect repellant and 
antimicrobial agent44.Although triterpenoids have rather limited medicinal use, recent studies 
indicate their great potential as drugs45. Ursolic acid has shown significant cytotoxicity in the 
lymphocytic leukemia cells P388 (ED50= 3.15 mg/mL) and L1210 (ED50= 4.00 mg/mL), as 
well as the human lung carcinoma cells A-549 (ED50= 4.00 mg/mL)46. The antitubercular 
activity of ursolic acid has also been reported47.     
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Table 4. The structure of previously isolated compounds 
 
      General structure         Compound name 
OAc
Me
Me
Me
C
 
Terpinyl acetate 
Me
Me
Me
 
α- pinene 
Me
Me
Me
O
 
Eucalyptol 
Me
Me
Me
MeMe
Me Me
CO 2H
HO
H
H
H
S
S
S
S
R
R
R
R
RS
Ursolic acid 
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Me
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MeMe
CO 2H
HO
HO
H
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R
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S
R
S
R
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Maslinic acid 
Me
Me
Me
Me
Me
Me Me
O
O
HO
 
11, 12-Dehydroursolic acid 
lactone 
Me
O
O
O
O OH
OH
OH
OH
OH
HO
OH
S
R
R
S R
Quecimelin 
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2. Results and Discussion 
 
 
 Eucalyptus viminalis was selected for this  investigation because the methylene chloride 
extract was  reported to possess activity against lung cancer.  The plant material( dried leaves) 
were collected in Russia and extracted first with methylene chloride and then with methanol. 
Methylene chloride extract was chromatographed on silica gel and then eluted with mixed 
solvents of increasing polarity (hexane, methylene chloride, chloroform, and methanol) to obtain 
81 fractions. The eluent fractions were collected and monitored by TLC on silica gel with 
different solvent systems: hexane to methylene chloride=20%:80% or hexane to methylene 
chloride=50%:50%. The hexane/methylene chloride fractions 1-32 from the first column were 
further chromatographed to obtain 12 fractions.  Fractions 3-6 were mixed, chromatographed in a 
small liquid chromatography column. From the resulting fraction a pure compound was isolated, 
which was proved to be β-amyrin formate, with a jelly consistency and light yellow color. The 
chromatography results are given in Table 5 and Table 6.  
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Table 5. Column chromatography (I) of Eucalyptus viminalis Labill 
 
      Fractions               Eluent         Weight ( grams ) 
     F 1-5            100% hexane                 0.56 
     F 6-11    20%CH2Cl2 in hexane                 0.68 
      F 12-15    30%CH2Cl2 in hexane                 1.59 
      F 16-23   40%CH2Cl2 in hexane                 1.83 
      F 24-31   50%CH2Cl2 in hexane                 2.83 
      F 32-42   60%CH2Cl2 in hexane                 7.31 
      F 43-50   70%CH2Cl2 in hexane                 4.74 
      F 51-58   80%CH2Cl2 in hexane                 3.57 
      F 59-70       100%CH2Cl2                 3.70 
      F 71-78   50% CH2Cl2 in CHCl3                1.32 
       F 79-81       100%CH3OH                1.89 
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Table 6. Column chromatography (II) of Eucalyptus viminalis Labill 
 
         Fractions                    Eluent         Weight ( grams ) 
            F 1-2            100% hexane                 0.30 
            F 3-4    20%CH2Cl2 in hexane                 0.40 
            F 5-6    50%CH2Cl2 in hexane                 0.31 
            F 7    75%CH2Cl2 in hexane                 0.48 
            F 8    100%CH2Cl2                 0.49 
            F 9   50% CH2Cl2 in CHCl3                 2.13 
            F 10       100% chloroform                2.00 
           F 11-12  50% CHCl3in CH3OH                4.17 
 
 
 The UV spectrum of β-amyrin formate shows the following absorption maxima λmax: 200 
nm, 276 nm, and 340 nm, suggesting that the compound has double bonds, methyl and other 
substituents attached to the rings. The UV spectrum is given in Figure 9. 
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Figure 9. UV spectrum of β-amyrin formate 
 
 
 The IR spectrum (Figure 10) indicated absorption maxima λmax at 2851 cm-1 (C-H stretch 
absorptions), 1730 cm-1 (aldehydic stretch), 1649 cm-1 (double bond six membered ring), 1471, 
1380 cm-1 (C-O stretch), 1174 cm-1 (C-O stretch), 850 cm-1 (C-H out-of-plane bend) , which are 
consistent with the values of the previously isolated compound. 
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 Figure 10. IR spectrum of β-amyrin formate 
 
 
 Another spectroscopic method used to check the purity of isolated compound was gas 
chromatography. The retention time is the time between injection of a sample and the appearance 
of a solute peak at the detector of a chromatographic column. The gas chromatogram (Figure 11) 
shows a single peak with retention time  tr = 14.17 min. 
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 Figure 11. Gas Chromatogram of β-amyrin formate 
 
 
 High-performance liquid chromatography (HPLC) is used for separating and determining 
species in different materials. Normal phase HPLC was performed utilizing several solvent 
systems that are normally used and the best results were obtained with hexane and methylene 
chloride (20%:80%). The chromatogram is presented in Figure 12. 
 40
 Figure 12. HPLC of β-amyrin formate 
 
 
 Upon mass spectral analysis (Figure 13) β-amyrin formate gave an M peak at m/z 
454.7226 which corresponds to the molecular formula C31H50O2. Amyrin series are characterized 
by the presence of a 12-13 double bond. This feature is being recognized by mass spectrometry, 
since the molecular ion undergoes the equivalent of a retro-Diels-Alder fragmentation to provide 
a very characteristic peak due to an ion with a mass of 218.2044. 
The fragmentation pattern of the β-amyrin formate consists of molecular ion M= 454.7226, M-
COOH= 409.3875, a characteristic signal for triterpenes M-236.5182= 218.2044.  
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 Figure 13. Mass spectrum of β-amyrin formate 
 
 
 The basic fragmentation pattern of the proposed structure is illustrated in Figure 14. The 
dominant fragmentation cleavage of the molecular ion m/z 454 bond takes place directly, to yield 
the triterpenyl ion C30H49, m/z 409.48 This is followed by fragmentation of the triterpadiene 
moiety.  
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Figure 14. Scheme summarizing the mass fragmentation pattern of β-amyrin formate 
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The occurrence of the isolated compound (β-amyrin formate) was reported first time by S. 
Malhotra and al. in 1987, who extracted it from Canarium strictum gum.49 This structure is 
shown in Figure 15. 
 
29 30 
O
C
O
H
20 19 21 
22 18 
12 17 25 11 13 
28 26 16 
15 14 9 1 
2 10 
7 
8 
27 3 5 
6 4 31 
23 24  
Figure 15. Structure of β-amyrin formate 
 
 
 The parent β-amyrin is a widely occurring triterpene and was identified in the extract by a 
combination of MS, IR, 1HNMR, 13CNMR, and DEPT experiments. The spectra were run in 
deuterated acetone and deuterated chloroform. The assignments of the 13C signals confirmed 
those made by Knight in 1974, based on the analysis of the chemical shifts in a series of 
triterpenoids and their derivatives.50 In order to confirm the proposed structure, the 13C-NMR,  
1H-NMR spectra of β-amyrin formate were obtained. The 1H-NMR spectrum revealed two peaks 
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at δ 4.51 ppm (t) and δ 9.81 ppm (s). The former signal was assigned to the methine proton on 
C3 (Figure 15) and the latter was ascribed to that of formyl proton (C31, Figure 15). The single 
hydrogen attached to the C-12 gave a peak at 5.2 ppm. Also, the peaks between 0.6 and 1.2 ppm, 
correspond to methyl groups (CH3 - 8 groups), and the peaks between 1.2 and 2.9 ppm 
correspond to the methylene groups (CH2 - 10 groups). The 1H-NMR spectrum (Figure 16) did 
not show a good separation of the peaks (between δ 0.00 ppm and δ 2.00 ppm), thus the proton 
peaks are not resolved. That is why the 13C-NMR was chosen for the final structure 
confirmation, besides MS and IR. However, the spectral assignments could be precisely obtained 
by using HMQC and DQCOSY spectroscopy. 
 
Figure 16. 1H-NMR spectrum of β-amyrin formate 
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The DEPT 13C-NMR spectrum (Figure 18) revealed the methyl carbons appear at δ 23.81 (C-23 
and C-24), δ 15.76 (C-25), δ 16.22 (C-26), δ 25.64 (C-27), δ 28.73 (C-28), δ 28.93 (C-29 and C-
30). Methylene carbons appear at δ 22.53 (C-2), δ 38.25 (C-1), δ 18.27 (C-6), δ 32.91 (C-7), δ 
26.81 (C-15), δ 26.95 (C-16), δ 37.92 (C-22), δ 33.94 (C-21), δ 47.52 (C-19), δ 23.91 ppm (C-
11). Methyne carbons appear at δ 83.13 (C-3), δ 47.73 (C-18), δ 57.92 (C-5), δ 121.63 (C-12), δ 
47.53 (C-9), δ 41.74 ppm (C-14). Quaternary carbons appear at δ 42.82 (C-4), δ 38.52 (C-8), δ 
41.74 (C-14), δ 32.83 (C-17), δ 30.11 (C-20), δ 145.22 (C-13), δ 37.75 (C-10) and δ162.11 ppm 
(C-31). A general 13C-NMR spectrum is shown on Figure 17. 
 
 
Figure 17. 13C-NMR spectrum of β-amyrin formate  
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 Figure 18. 13C-NMR DEPT spectrum of β-amyrin formate 
 
 
 The MS, IR, 1H-NMR, 13C-NMR data confirms the structure of β-amyrin formate. This 
pure compound was also tested against colon and breast cancer. The bioassay revealed that β-
amyrin formate has -15% inhibition against colon cancer, but did not possess activity against 
breast cancer. The results are shown in Figure 19. Based on bioassay tests, this compound might 
be considered for studies related to the mechanism of action. The procedure and interpretation of 
data were presented in the first part of this thesis. 
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 Figure 19. Effect of β-amyrin formate relative to the growth of colon cancer cells 
 
 
 The conclusion of this study is represented by the extraction, isolation and structure 
confirmation of a known pure compound, β-amyrin formate, which was isolated from dried 
leaves of Eucalyptus viminalis Labill. Also, it is presented like a possible drug lead against colon 
cancer and can be recommended for further investigation. However, this is the first report of 
isolation of β-amyrin formate from Eucalyptus viminalis Labill and the first test of this 
compound against colon cancer.  
 
   
 
 
 
 48
3. Experimental 
 
3.1. General experimental procedure 
 
 
UV spectrum was obtained in hexane with a Carry 500 scan UV-NIR-spectrophotometer and the 
absorption maximum is given in nm. IR spectrum was recorded on a Perkin Elmer Spectrum One 
FT-IR spectrometer. The NMR experiments were run on a Varian 300 MHz and the solvents 
used were deuterated chloroform and acetone. GC-MS spectra were recorded on Trace GC/Trace 
DQC from Finnigan. A capillary column of RTX-5MS with a length of 15 m and 0.25 mm ID 
was used. The oven temperature was initially set up to 80°C for 5 minutes than programmed to 
reach 250°C.  HPLC was run on Gilson equipment, using a silica-gel column normal phase and 
the solvent used was a mixture of hexane and methylene chloride. 
      
3.2 Extraction, isolation, characterization and cancer bioassay 
 
 
The plant material, Eucalyptus viminalis, was received from Russia. The dried leaves (2.00 Kg) 
were extracted in methylene chloride and methanol using a Soxhlet device. After extraction in 
methylene chloride 156.00 grams of material were obtained. Column chromatography was 
carried out on silica gel (E. Merk, 70-230 mesh). Pre-coated preparative silica gel GF-254 plates 
(20×20 cm, 0.5 mm thick, E. Merk) were used for thin layer chromatography (TLC). 
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Spectrum of β-amyrin formate shows the following absorption maxima λmax: 200 nm, 276 nm, 
and 340 nm, The IR spectrum indicated absorption maxima λmax at 2851, 1730, 1649, 1471, 
1380, 1174, 850 cm-1. 
GC (tr 14.17 min, Figure 11), HPLC (tr 9.53), MS  m/z: M = 454.7226, 409.3875, 218.2044. 13C 
NMR chemical shifts from C1 to C31 :δ38.25, 22.53, 83.13, 42.82, 57.92,18.27,32.91, 38.52, 
47.53, 37.75, 23.91, 121.63, 145.22, 41.74, 26.81, 26.95, 32.83, 47.73, 47.52, 30.11, 33.94, 
37.92, 23.81 (C23, C24), 15.76, 16.22, 25.64, 28.73, 28.93 (C29, C30), 162.11 ppm.   
In the cancer bioassay, 0.0002g of compound was used and the procedure was described on the 
first part of this thesis. 
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